Bravecto

Bravecto. It is a veterinary pharmaceutical product used to kill parasites on dogs and cats, including fleas and ticks. The active ingredient is fluralaner, which belongs to the Isoxazoline class of compounds. It is manufactured by the global animal health company Merck Animal Health and is available in both chewable tablet and topical solution formulations.

Description and mechanism of action

Bravecto contains the active pharmaceutical ingredient fluralaner, a member of the Isoxazoline family. This class of compounds functions by selectively inhibiting the function of GABA-gated and glutamate-gated chloride channels in the nervous system of invertebrates. This disruption leads to uncontrolled neuronal activity, paralysis, and death of the target parasite. The drug exhibits high selectivity for these channels in arthropods, resulting in a wide margin of safety in mammals like dogs and cats. Its unique pharmacokinetic profile allows for sustained release from body tissues, providing long-lasting efficacy from a single dose.

Clinical uses and efficacy

Bravecto is indicated for the treatment and prevention of flea infestations by Ctenocephalides felis and for the treatment and control of various tick species, including Ixodes scapularis, Dermacentor variabilis, and Rhipicephalus sanguineus. It is also used against mite infestations such as Sarcoptes scabiei and Otodectes cynotis, and for the treatment of demodicosis caused by Demodex canis. Clinical studies conducted by organizations like the European Medicines Agency have demonstrated high efficacy, often exceeding 90%, against these parasites for up to 12 weeks in dogs and 8 weeks in cats from a single administration. This extended duration provides a significant advantage over many monthly treatment protocols.

Safety and side effects

The safety profile of Bravecto has been evaluated in numerous field and laboratory studies. The most commonly reported adverse events in dogs are mild and transient gastrointestinal disturbances, such as vomiting and diarrhea, along with occasional lethargy and anorexia. In cats, similar gastrointestinal signs, as well as pruritus and alopecia at the application site for the topical solution, have been observed. Post-marketing surveillance has reported rare instances of more serious neurological events, including seizures, though a definitive causal relationship has not been conclusively established. Use is contraindicated in puppies and kittens under specific age and weight thresholds as determined by regulatory bodies like the Food and Drug Administration.

Regulatory history and approvals

Fluralaner was originally developed by the Japanese pharmaceutical company MSD Animal Health. It received its first market authorization in the European Union in 2014 following a positive opinion from the European Medicines Agency. Subsequent approvals were granted by the Food and Drug Administration in the United States and by regulatory authorities in other major markets including Australia, Canada, and Japan. The approval process involved the submission of extensive data from clinical trials demonstrating safety, efficacy, and quality to agencies like the Committee for Medicinal Products for Veterinary Use. These approvals cover both the oral and topical formulations for use in companion animals.

Environmental impact and resistance concerns

As a systemic parasiticide, concerns exist regarding the environmental fate of fluralaner and its potential impact on non-target organisms, particularly invertebrates in aquatic and terrestrial ecosystems. Excretion of the compound in pet feces could lead to low-level environmental exposure. While specific ecotoxicological studies are part of the regulatory dossier for the European Medicines Agency, ongoing monitoring is recommended. Furthermore, the widespread use of any parasiticidal agent raises the potential for the development of drug resistance in parasite populations, a phenomenon well-documented with other classes like macrocyclic lactones. Organizations such as the World Health Organization emphasize the importance of stewardship programs to mitigate resistance development in veterinary and public health contexts.

Category:Veterinary drugs Category:Antiparasitic agents